Eric T Gangl

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 2

Top Topics

Antiretroviral Therapy

Nitric Oxide Synthase

Men Who Have Sex With Men

Acute Myeloid Leukemia

Top Venues

Cancer research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh C Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I Fisher, Eric T Gangl, Hilary J Lewis, Dawn Trueman, Neha Wali, Stuart Charles Williamson, Jennifer I Moss, Elodie Montaudon, Héloïse Derrien, Elisabetta Marangoni, Ricardo J Miragaia, Sladjana Gagrica, Pablo Morentin Gutierrez, Thomas Moss, Gareth A Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E Critchlow, James S Scott, Justin P O Lindemann, Simon T Barry, Teresa Klinowska, Christopher J Morrow, Larissa S Carnevalli
The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. Cancer research (2023)
Aatman S Doshi, Susan Cantin, Marylens Hernandez, Srimathi Srinivasan, Sharon Tentarelli, Matthew Griffin, Yanjun Wang, Petar Pop-Damkov, Laura B Prickett, Cecilia Kankkonen, Minhui Shen, Maryann San Martin, Song Wu, M Paola Castaldi, Hormas Ghadially, Jeffrey Varnes, Sonya Gales, David Henry, Clare Hoover, Deanna A Mele, Iain Simpson, Eric T Gangl, Scott N Mlynarski, M Raymond V Finlay, Lisa Drew, Stephen E Fawell, Wenlin Shao, Alwin G Schuller
Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners. Molecular cancer therapeutics (2023)